Waypoint Bio raises $20M for AI-validated cell therapies

Waypoint Bio is using spatial biology and AI to validate in vivo CAR-T candidates for solid tumors before costly clinical trials.

Waypoint Bio is using spatial biology and AI to validate in vivo CAR-T candidates for solid tumors before costly clinical trials.

The broader signal is that AI is moving from demos into budgets, rules, security procedures and capital allocation.

Sources: BusinessWire; BioSpace; Precision Medicine Online; CocoLoop, CocoLoop.